Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and/or fluzoparib for platinum-resistant recurrent ovarian cancer
ChiCTR2100054939Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Shandong First Medical University
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of bevacizumab and fluzoparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Second Affiliated Hospital of Shandong First Medical University. Primary endpoint: Progression-free survival. Started Dec 2021; status: recruiting.
02
Drugs
bevacizumabfluzoparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2100054939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054939.